Filling the need for trusted information on national health issues

Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.

  • Your Selections:

Refine Results

date

Topics

Content Type

Tags

The Role of Clinical and Cost Information in Medicaid Pharmacy Benefit Decisions: Experience in Seven States

This policy brief provides perspective on the potential for using comparative effectiveness research in Medicaid pharmacy programs by looking at seven states to determine how they currently evaluate relative clinical and cost information about prescription drugs when making coverage decisions for their Medicaid pharmacy benefits. The brief was prepared by…

Medicare Part D Data Spotlight: A First Look at Part D Plan Offerings in 2012

This data spotlight examines the stand-alone Part D drug plan options available to Medicare beneficiaries in 2012. Medicare beneficiaries will, on average, be able to choose from 31 stand-alone Medicare Part D prescription drug plans to choose from, a new Kaiser analysis finds. Average premiums would increase by 4 percent…

National Surveys of Pharmacists and Physicians, Findings on Medicare Part D

Two national surveys conducted and analyzed by the Kaiser Family Foundation show that substantial majorities of pharmacists and physicians believe that the prescription drug law is helping people on Medicare save money on their medications. At the same time, a majority in both professions report that Medicare beneficiaries who they…

Medicare Part D Update: Lessons Learned and Unfinished Business

Enacted in 2003, Medicare’s Part D prescription drug benefit reflected an unprecedented and controversial new approach for Medicare, relying exclusively on private plans to provide health coverage and including an unusual gap in coverage. This analysis by Kaiser researchers examines in detail how the new model has worked since its…

A Side-by-Side Comparison of the Prescription Drug Coverage Provisions of S.1 and H.R. 1

This document, prepared by Health Policy Alternatives, Inc., provides a detailed side-by-side comparison of the prescription drug provisions of the House and Senate Medicare proposals, as passed on June 27, 2003. Along with these provisions, the side-by-side compares the major provisions relating to the role of private health plans in…

Health News Index January/February 2002

Health News Index January/February, 2002 The January/February 2002 edition of the Kaiser Family Foundation/ Harvard School of Public Health Health News Index includes questions about major health stories covered in the news, including the public s knowledge of the ongoing anthrax investigation and prescription drug discount cards. The Health News…

Savings for Medicare Beneficiaries from the Use of Prescription Drug Discount Cards

This article, published online by Health Affairs on April 14, 2004, estimates the extent to which prescription drug discount cards could affect out-of-pocket spending by Medicare beneficiaries who lack drug coverage, based on an analysis of the Medicare Current Beneficiary Survey. The Medicare discount card program is scheduled to go…

Health Care Agenda for the New Congress – Toplines

This document includes the complete toplines from a survey of the public’s attitudes regarding the health care agenda for Bush’s second term and the new Congress in 2005. It assesses the relative priority placed on health-care concerns by the American public and also provides insight into public opinion on key…